Company intelligence / Profile preview

Cognetix

Salt Lake City, Utah, United Statescognetix-llc.com ↗

Ownership: Private
Development stage: Other

Overview

Cognetix was a biopharmaceutical company established in the early 1990s that focused on developing novel therapeutics derived from marine snail toxins, particularly conotoxins. Its lead program, CGX‑1002, targeted sodium channels for pain management but was discontinued. The company is now dissolved and no longer active as of May 2025. There are no current clinical results or ongoing pipeline programs.

Therapeutic areas: Neurology
Modalities: PeptidesSmall moleculeBiologic
Industry: Biotech

Drug pipeline

2 assets

conantokin-G

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Cognetix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cognetix.

Explore the full profile